China Resources Pharmaceuticals (03320.HK): Steady growth in performance, high-quality epitaxial expansion to expand new growth points
China Resources Pharmaceutical (03320.HK): Performance meets expectations and further deepens marketing system transformation
Haitong International: Maintaining China Resources Pharmaceutical's (03320) “Better Than Market” Rating Target Price of HK$8.12
China Resources Pharmaceuticals (3320.HK): Endogenous epitaxial expansion of business layout resources to achieve sustainable growth
China Resources Pharmaceuticals (3320.HK): Accelerate and improve business layout and steadily release performance potential
Nomura Adjusts CR Pharmaceutical Group's Price Target to HK$8.80 From HK$9.08, Keeps at Buy
China Resources Pharmaceutical (03320.HK): The commercial sector introduces equity incentives for strategic investors and industrial subsidiaries, and the launch is expected to revitalize various sectors
Big Bank Rating | Damo: I believe China Resources Pharma's stock price will increase its rating within 30 days to “gain weight”
China Resources Pharmaceutical (3320.HK): Continued optimization of China Resources Pharmaceutical's investment capital structure in the commercial introduction war
China Resources Pharmaceutical (03320.HK): Steady growth in performance and continuous improvement in operating capacity
Bank Rating|Damo: China Resources Pharmaceutical's stock price is expected to rise by HK$8 in the next 15 days
China Resources Pharmaceutical (3320.HK): Improving the profitability of the main business and continuous optimization of the business structure
China Resources Pharmaceutical (03320.HK): 1H23 performance is in line with expectations for an increase in gross margin in the industrial sector
China Resources Pharmaceutical (3320.HK) 23 Annual Report Review: All Businesses Achieved Good Growth, Exchange Rates Affect Apparent Growth Rate
Nomura Adjusts China Resources Pharmaceutical Group's Price Target to HK$9.08 From HK$9.32, Keeps at Buy
Nomura: Maintaining China Resources Pharmaceuticals (03320)'s “buy” rating, the target price fell to HK$9.08
China Resources Pharmaceutical (3320.HK): The “14th Five-Year Plan” Strategic Plan is Clear, and Endogenous Outreach Goes Hand in Hand
Big Bank Ratings | Daimo: Raising the target price of China Resources Pharmaceutical (3320.HK) to HK$7.6 to “increase holdings”
Big Bank Ratings | Lyon: Raising the target price of China Resources Pharmaceuticals (3320.HK) to HK$8.39 to “buy”
China Resources Pharmaceutical (03320.HK): Profits are in line with expectations, further optimization of the business sector
No Data